Treatment of patients with acute promyelocytic leukemia: A consensus statement on risk-adapted approaches to therapy

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue SUPPL. 3, 2010, Pages

  Tallman, Martin ^a   Douer, Dan ^b   Gore, Steven ^c   Powell, Bayard L ^d   Ravandi, Farhad ^e   Rowe, Jacob ^f   Ranganathan, Aarati ^g   Sanz, Miguel A ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d WAKE FOREST BAPTIST HEALTH   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f RAMBAM MEDICAL CENTER   (Israel)

^g Physicians' Education Resource   (United States)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

All trans retinoic acid; APL; Arsenic trioxide; Cytarabine; Maintenance therapy

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; STEROID; TAMIBAROTENE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CONSENSUS; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; HYPERTRANSAMINASEMIA; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; POINT MUTATION; PROMYELOCYTIC LEUKEMIA; THROMBOCYTE COUNT; VEIN OCCLUSION;

EID: 79955817722     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.s.023     Document Type: Article

References (35)

1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly urable. Blood 2008; 111:2505-15.
2. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875-91.
3. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105:3019-25.
4. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007; 20:57-65.
5. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; [Epub ahead of print].
6. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acutepromyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103:1237-43. (Pubitemid 38168633)
7. Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008; 112:3130-4.
8. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395-402.
9. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96:1247-53. (Pubitemid 30658450)
10. Bassan R, Battista R, Viero P, et al. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia 1995; 9:238-43.
11. Tallman MS, Kim HT, Schiffer CA, et al. Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the ATRA era: A report of 153 patients treated on Intergroup 0129 and Pethema LPA96 and LPA99. Blood 2004; 104: (abstract 394).
12. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16:1959-73. (Pubitemid 35203438)
13. Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology (Am Soc Hematol Educ Program) 2006; 156-61, 514.
14. Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93:4131-43. (Pubitemid 29279255)
15. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94:1192-200. (Pubitemid 29380399)
16. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-21.
17. Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (< or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 2003; 17:1085-90. (Pubitemid 36722237)
18. Sanz MA, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104:3490-3. (Pubitemid 39564417)
19. Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24:5703-10. (Pubitemid 46631312)
20. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults patients younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; [Epub ahead of print].
21. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008; 111:1078-84. (Pubitemid 351213385)
22. Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115:5137-46.
23. Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010; 28:1047-53.
24. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106:3342-7.
25. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504-10.
26. Clinicaltrials.gov [Web site]. A phase II study of ATRA, arsenic trioxide and gemtuzumab ozogamicin in patients with previously untreated high-risk acute promyelocytic leukemia. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00551460. Accessed: May 12, 2010.
27. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114:5126-35.
28. Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 2010; 115:1690-6.
29. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94:3015-21. (Pubitemid 29512705)
30. Montesinos P, Gonzalez JD, Gonzalez J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 2010; 28:3872-9.
31. Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol 2002; 81:504-7. (Pubitemid 36075502)
32. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100:4298-302. (Pubitemid 36001941)
33. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who had become negative for PML-RAR transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 Study. Blood 2006; 108: (abstract 2009).
34. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group. Blood 2004; 104:392a.
35. ClinicalTrials.gov [Web site]. Assessment of the optimal timing of chemotherapy with or after ATRA and the role of maintenance. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00599937. Accessed: July 7, 2010.